Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $4.82M | $0.07 |
| 2024 | $0.00 | $-67.56M | $-1.81 |
| 2023 | $0.00 | $-81.41M | $-3.98 |
| 2022 | $0.00 | $-54.60M | $-4.82 |
| 2021 | $1.50M | $-40.59M | $-4.73 |
Social Signal Score
Earnings
Mon, Nov 16(in 3 months)
Consensus estimate $-0.02 per share
Typical surprise +2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.18 vs $-0.03beat
- Thu, May 14$-0.46 vs $-0.04miss
- Mon, Mar 16$-0.23 vs $-0.07miss
- Wed, Nov 12$-0.08 vs $-0.24beat
- Thu, Aug 14$-0.40 vs $-0.29miss
- Tue, May 13$-0.37 vs $-0.38beat
Estimates and results for CYPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.11
- Implied price
- $1.71
- Return from $0.64
- 21.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.85 — today's price is already 24.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -2.0% | 4.2% | 7.5% | 10.4% | 13.0% | 15.4% |
| 3.0% | 9.5% | 12.9% | 16.0% | 18.8% | 21.3% |
| 8.0% | 14.8% | 18.4% | 21.6% | 24.5% | 27.2% |
| 13.0% | 20.1% | 23.9% | 27.3% | 30.3% | 33.1% |
| 18.0% | 25.5% | 29.4% | 32.9% | 36.1% | 39.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsprnewswire.com·3d ago·Negative
Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1-high 2L mCRC patients, sirexatamab improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Leap Therapeutics, Inc., the biotechnology subsidia
View source ↗